Kenvue Inc. (NYSE:KVUE) Shares Acquired by Pinnacle Financial Partners Inc

Pinnacle Financial Partners Inc lifted its stake in shares of Kenvue Inc. (NYSE:KVUEFree Report) by 12.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,539 shares of the company’s stock after purchasing an additional 1,570 shares during the quarter. Pinnacle Financial Partners Inc’s holdings in Kenvue were worth $313,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Clearstead Advisors LLC acquired a new stake in Kenvue in the 3rd quarter valued at approximately $25,000. Planned Solutions Inc. acquired a new stake in Kenvue in the 4th quarter valued at approximately $27,000. AdvisorNet Financial Inc acquired a new stake in Kenvue in the 3rd quarter valued at approximately $28,000. Global Retirement Partners LLC acquired a new stake in Kenvue in the 3rd quarter valued at approximately $28,000. Finally, Venturi Wealth Management LLC acquired a new stake in Kenvue in the 3rd quarter valued at approximately $28,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KVUE has been the topic of several analyst reports. William Blair began coverage on Kenvue in a research report on Wednesday. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. decreased their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. The Goldman Sachs Group began coverage on Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price target for the company. UBS Group increased their price target on Kenvue from $20.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, December 19th. Finally, Royal Bank of Canada decreased their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $25.42.

Read Our Latest Research Report on KVUE

Kenvue Trading Down 2.4 %

Shares of Kenvue stock opened at $20.33 on Thursday. The business has a fifty day simple moving average of $20.04 and a 200-day simple moving average of $20.23. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80.

Kenvue (NYSE:KVUEGet Free Report) last issued its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.28 by $0.03. The business had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. Equities analysts predict that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were given a $0.20 dividend. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 annualized dividend and a dividend yield of 3.94%.

Kenvue Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

See Also

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.